Trial Outcomes & Findings for Performance Comparison of Two Monthly Replacement Silicone Hydrogel Multifocal Lens Types (NCT NCT06232590)

NCT ID: NCT06232590

Last Updated: 2025-02-12

Results Overview

Subjective rating collected in office using a 0-100 scale, where 0=Very difficult and 100=Very easy. The participant rated the study lens considering a typical day in the last 1 month of wear.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

60 participants

Primary outcome timeframe

1 month

Results posted on

2025-02-12

Participant Flow

Participant milestones

Participant milestones
Measure
Control Lens, Then Test Lens
Participants wore the Control Lens for 1 month, then the Test Lens for 1 month
Test Lens, Then Control Lens
Participants wore the Test Lens for 1 month, then the Control Lens for 1 month
Period 1: First Intervention
STARTED
30
30
Period 1: First Intervention
COMPLETED
30
30
Period 1: First Intervention
NOT COMPLETED
0
0
Period 2: Second Intervention
STARTED
30
30
Period 2: Second Intervention
COMPLETED
29
30
Period 2: Second Intervention
NOT COMPLETED
1
0

Reasons for withdrawal

Reasons for withdrawal
Measure
Control Lens, Then Test Lens
Participants wore the Control Lens for 1 month, then the Test Lens for 1 month
Test Lens, Then Control Lens
Participants wore the Test Lens for 1 month, then the Control Lens for 1 month
Period 2: Second Intervention
Unable to attend study visit
1
0

Baseline Characteristics

Race and Ethnicity were not collected from any participant.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Overall Study
n=59 Participants
Participants who completed all study visits.
Age, Continuous
53.2 years
STANDARD_DEVIATION 6.7 • n=59 Participants
Sex: Female, Male
Female
40 Participants
n=59 Participants
Sex: Female, Male
Male
19 Participants
n=59 Participants

PRIMARY outcome

Timeframe: 1 month

Subjective rating collected in office using a 0-100 scale, where 0=Very difficult and 100=Very easy. The participant rated the study lens considering a typical day in the last 1 month of wear.

Outcome measures

Outcome measures
Measure
Control Lens
n=59 Participants
Participants that received the Control Lens and completed all study visits.
Test Lens
n=59 Participants
Participants that received the Test Lens and completed all study visits.
Lens Handling for Insertion
95 score on a scale
Standard Deviation 9
96 score on a scale
Standard Deviation 8

Adverse Events

Control Lens

Serious events: 0 serious events
Other events: 4 other events
Deaths: 0 deaths

Test Lens

Serious events: 0 serious events
Other events: 4 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
Control Lens
n=60 participants at risk
All participants that received the Control Lens.
Test Lens
n=59 participants at risk
All participants that received the Test Lens.
Eye disorders
Small lymph cysts
0.00%
0/60 • Length of study, approximately 3 months
1.7%
1/59 • Number of events 2 • Length of study, approximately 3 months
Eye disorders
Subconjunctival hemorrhage
1.7%
1/60 • Number of events 1 • Length of study, approximately 3 months
0.00%
0/59 • Length of study, approximately 3 months
Eye disorders
Eye floaters
0.00%
0/60 • Length of study, approximately 3 months
1.7%
1/59 • Number of events 1 • Length of study, approximately 3 months
Respiratory, thoracic and mediastinal disorders
Respiratory infection
1.7%
1/60 • Number of events 1 • Length of study, approximately 3 months
1.7%
1/59 • Number of events 1 • Length of study, approximately 3 months
Gastrointestinal disorders
Stomach distress
0.00%
0/60 • Length of study, approximately 3 months
1.7%
1/59 • Number of events 1 • Length of study, approximately 3 months
Psychiatric disorders
Depression
1.7%
1/60 • Number of events 1 • Length of study, approximately 3 months
0.00%
0/59 • Length of study, approximately 3 months
Surgical and medical procedures
Primary care provider intervention
1.7%
1/60 • Number of events 1 • Length of study, approximately 3 months
0.00%
0/59 • Length of study, approximately 3 months

Additional Information

José A. Vega

CooperVision Inc.

Phone: +1 (925) 621-3761

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place